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Hypoxia is an important micro-environmental characteristic of rheumatoid arthritis
(RA). Hypoxia-inducible factors (HIF) are key transcriptional factors that are highly
expressed in RA synovium to regulate the adaptive responses to this hypoxic milieu.
Accumulating evidence supports hypoxia and HIFs in regulating a number of important
pathophysiological characteristics of RA, including synovial inflammation, angiogenesis,
and cartilage destruction. Experimental and clinical data have confirmed the upregulation
of both HIF-1α and HIF-2α in RA. This review will focus on the differential expression
of HIFs within the synovial joint and its functional behavior in different cell types to
regulate RA progression. Potential development of new therapeutic strategies targeting
HIF-regulated pathways at sites of disease in RA will also be addressed.
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INTRODUCTION
Rheumatoid arthritis (RA) is the most common form of inflammatory arthritis. It is an
autoimmune and polyarthritic condition, characterized by inflammation of the synovium
(synovitis), progressive cartilage destruction, and bone erosion, which ultimately results in loss
of integrity of the affected joints (Lautenbach et al., 2013). The RA synovium is enriched with a
variety of cell types, including synovial fibroblasts, immune cells (e.g., mast cells, macrophages,
neutrophils, dendritic cells, B cells, and T cells; Hitchon and El-Gabalawy, 2011), and newly
formed blood vessels from the pre-existing vasculature (angiogenesis; Paleolog, 2002) (Figure 1).
Hypoxia is an important micro-environmental characteristic of RA (Lund-Olesen, 1970; Hitchon
and El-Gabalawy, 2004; Gaber et al., 2005; Konisti et al., 2012). This is mainly due to hyperplasia
of the synovial lining and increased infiltration of immune cells, which together enhance the
synovial demand for oxygen (Peters et al., 2004; Lee et al., 2007; Jeon et al., 2008). Induction of
angiogenesis is likely a consequence of synovial hypoxia in RA (Paleolog, 2002). However, this
increased neovascularization, primarily of dysregulated and immature blood vessels, is unable to
provide adequate oxygen perfusion to balance the increased demand (Distler et al., 2004; Taylor
and Sivakumar, 2005; Kennedy et al., 2010). Analysis of the oxygen tension (pO2) levels in the
synovial fluid of knee joints in RA patients have consistently shown significantly lower levels (51.0
± 16.5mmHg) in comparison to patients with osteoarthritis (79.2 ± 14.0mmHg), despite similar
synovial thickness scores (Lee et al., 2007). This suggests that synovial proliferation may contribute
more to hypoxia in the joint cavities of RA patients.
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In response to the alterations in oxygen tension, hypoxia-
inducible factors (HIFs) are activated as an adaptive mechanism.
HIFs are considered the “master regulators” (Imtiyaz and Simon,
2010), and belong to the family of basic–helix-loop-helix/Per-
ARNT-Sim (bHLH/PAS) DNA binding transcription factors
(Greer et al., 2012). HIF-1 is a heterodimeric transcription factor,
composed of two subunits—HIF-1α and HIF-1β. HIF-1α is
regulated by oxygen levels and post-translational modifications
that are sensitive to oxygen levels, whereas HIF-1β is expressed
constitutively in the nucleus (Konisti et al., 2012). Three HIF-
α isoforms have been identified to date (HIF-1α, HIF-2α HIF-
3α), with HIF-1α being the most widely investigated (Fan et al.,
2014). Activation of the HIF pathway generally allows cells to
survive in a hypoxic environment (Semenza, 1998; Harris, 2002),
however in some cases these adaptive responses can accelerate
disease progression (Ikeda, 2005). Increasing evidence suggest
that HIFs play a major role in perpetuating the pathogenesis
of RA (Figure 1). In particular, HIF-1α can activate pathways
that lead to synovitis, angiogenesis, cartilage degradation, and
bone erosion (Konisti et al., 2012; Elshabrawy et al., 2015;
Biniecka et al., 2016; Hu et al., 2016). Recent studies have begun
to investigate the role of HIF-2α in RA, with initial results
demonstrating a potential role as a catabolic factor (Huber et al.,
2006; Ryu et al., 2014; Huh et al., 2015). This review will focus on
the differential expression of HIF within the synovial joint and
its functional behavior in different cell types to regulate disease
progression. Potential development of new therapeutic strategies
targeting HIF-regulated pathways at sites of disease will also be
addressed.
FIGURE 1 | Role of hypoxia-regulated HIF-α transcription factors in inflammation and destruction of the RA joint. HIF-α can directly modulate the
expression of mediators that are involved in synovitis, angiogenesis, cartilage destruction, and bone erosion. This can also influence the composition of the cellular
infiltrate in the synovial tissue and perpetuate the progression of disease.
HIF EXPRESSION WITHIN AFFECTED RA
JOINTS
HIFs are highly expressed in the hyperplastic RA synovium,
which primarily consists of fibroblast-like synoviocytes (FLS) and
macrophage-like synoviocytes (MLS; Hitchon et al., 2002). FLS
are key effector cells in the pathogenesis of RA, and are crucial
in initiating and driving RA together with inflammatory cells (Li
et al., 2013a). Studies have reported a patchy and generalized HIF
expression throughout the synovial tissue in both the nucleus
and cytoplasm (Giatromanolaki et al., 2003; Westra et al., 2010).
The degree of expression of the various HIF-α isoforms is only
beginning to be elucidated. HIF-1α is reported to be strongly
expressed in the intimal layer of the RA synovium, including in
resident macrophages (Hollander et al., 2001; Ahn et al., 2008). It
has also been detected in the sub-lining layer in lower amounts
(Hollander et al., 2001). Conversely, others have found HIF-1α
expression to be sparse in the RA synovium and reported HIF-2α
as the predominant isoform expressed in human RA joints and in
the collagen-induced arthritis (CIA) model (Ryu et al., 2014). In
particular, HIF-2α expression was mainly observed in FLS of the
RA synovium (Ryu et al., 2014). Furthermore, HIF-1α and HIF-
2α have also been identified in resident and infiltrating immune
cells (e.g., macrophages, T cell, and mast cells), chondrocytes,
and osteoclasts (Westra et al., 2010; Hardy et al., 2014; Ryu
et al., 2014). Understanding the expression of HIFs within the
RA joint allows us to better understand the degree in which they
are activated based on disease severity, as well as how they affect
particular cell types to contribute to perpetuating the disease.
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HIF AND INFLAMMATION
Synovitis is one of the major characteristics of RA. The synovium
is a thin and soft tissue lining that consists of the intimal lining
(intima) and an underlying loose connective tissue called the
sub-lining (sub-intima) layer (Smith, 2011). The architecture of
the synovium changes as the disease progresses, resulting in
significant tissue edema and hyper-proliferation of the synovial
cell lining to 10–15 layers (McInnes and Schett, 2011). The
sub-intimal layer becomes heavily infiltrated with immune cells
and undergoes neovascularization (McInnes and Schett, 2011).
Increasing evidence suggest that HIF-1α acts as a key regulator of
inflammation in RA (Eltzschig and Carmeliet, 2011) (Figure 1).
For example, PI3 kinase/Akt-mediated HIF-1α expression has
been shown to play a critical role in hypoxia-induced epithelial-
mesenchymal transition (EMT) phenotype transformation of
FLS, synovial hyperplasia, and inflammatory cell infiltration
in vivo in the CIA model (Li et al., 2013a). Conditional knock-
out of HIF-1α in animal models of RA demonstrated clinical and
histological improvement of experimental arthritis (Cramer et al.,
2003). In particular, there was a significant reduction in synovial
inflammation, pannus formation, and cartilage destruction in
HIF-1α knock-out mice (Cramer et al., 2003). Inhibition of HIF-
1α signaling also attenuated hypoxia-induced invasiveness of
activated FLS from the synovium of RA patients (Li et al., 2013b,
2015). Similarly, a recent study reported that HIF-2α itself is
capable of producing typical RA characteristics, with HIF-2α
deficient mice showing reduced development of experimental
arthritis (Ryu et al., 2014).
Inflammatory factors are known to upregulate the expression
HIF-1α and HIF-2α in RA. Pro-inflammatory cytokines such
as IL-1, TNF-α, and IL-33 have previously been reported to
increase the expression of HIF isoforms in synovial fibroblasts
(Thornton et al., 2000; Hu et al., 2013; Ryu et al., 2014) and
in animal models of RA (Xu et al., 2008; Hu et al., 2013; Ryu
et al., 2014). However, limited studies have investigated the
direct effect of HIFs in upregulating pro-inflammatory cytokines
in RA (Table 1). Recently, Hu et al. reported that HIF-1α
was able to directly potentiate the production of inflammatory
cytokines (IL-6, IL-8, TNF-α, and IL-1β) and cell-cell contact
mediators [IL-15, vascular cell adhesion molecule-1 (VCAM-1),
thrombospondin-1 (TSP-1), and stromal cell-derived factor-1
(SDF-1/CXCL12)] in rheumatoid arthritis synovial fibroblasts
(RASF; Hu et al., 2016). This was suggested to perpetuate
RASF and T-cell/B-cell interactions, leading to RASF-mediated
expansion of inflammatory Th1 and Th17 cells, as well as
autoantibody production. In particular, knocking down HIF-
1α in RASF inhibited IFN-γ, IL-17, and IgG production while
enhancing protective natural IgM secretion by T cells and B
cells (Hu et al., 2016). Co-expression of SDF-1 with HIF-1α
has been identified in both synovial tissue explants and synovial
fibroblasts (Hitchon et al., 2002; Hu et al., 2016). SDF-1 is a
chemokine that is upregulated in response to hypoxia in RA
(Hitchon et al., 2002; Santiago et al., 2011), and is involved
in a number of pathogenic events such as increased synovitis,
angiogenesis, bone erosion, and cartilage destruction (Villalvilla
et al., 2014). Upregulation of HIF-1α has also been shown
TABLE 1 | Direct effects of HIF-α on cells in the RA joint.
Cell type Mediator Source(s)
Synovial
fibroblasts
↑ IL-1β Hu et al., 2016
↑ IL-6 Hu et al., 2016
↑ IL-8 (CXCL8) Ahn et al., 2008; Hu
et al., 2016
↑ IL-15 Hu et al., 2016
↑ IL-17 Hu et al., 2016
↑ IL-33 Hu et al., 2013, 2016
↑ TNF-α Hu et al., 2016
↑ TNF-α converting enzyme Charbonneau et al.,
2007
↑ IFN-γ Hu et al., 2016
↑ SDF-1 (CXCL12) Hu et al., 2016
↑ MMP-1 Ahn et al., 2008; Lee
et al., 2012
↑ MMP-2 Li et al., 2013c
↑ MMP-3 Ahn et al., 2008
↑ MMP-9 Li et al., 2013c
↓ MMP-13 Lee et al., 2012
↑ VEGF Akhavani et al., 2009;
Hu et al., 2016
↑ EMT phenotype transformation Li et al., 2013a
↑ VCAM-1 Hu et al., 2016
↑ TSP-1 Hu et al., 2016
↑ IgG production Hu et al., 2016
↓ Protective natural IgM Hu et al., 2016
Myeloid cells ↑ TLR-4 Kim et al., 2010
↑ VEGF Fava et al., 1994
↑ CCL20 (MIP-3α) Bosco et al., 2008
Regulates glycolysis and energy
metabolism
Cramer et al., 2003









to significantly enhances the expression of IL-33, which is
then able to form a HIF-1α/IL-33 regulatory circuit to further
increase HIF-1α expression (Hu et al., 2013). TNF-α converting
enzyme, which is involved in regulating TNF-α levels, has also
demonstrated to be HIF-1α dependent in RA (Charbonneau
et al., 2007). The effect of hypoxia and HIFs in regulating
the expression of inflammatory factors is complex, as more
than one pathway may be involved in inducing expression. For
example, IL-6 expression was significantly increased in FLS under
hypoxic conditions, however there are contradictory reports of
the influence of HIF-1α on its expression (Ahn et al., 2008; Hu
et al., 2016).
Toll like receptors (TLR) are pattern recognition receptors
that are mainly expressed in immune cells and RASF cells
in RA to regulate inflammatory responses (Brentano et al.,
2005; Ospelt et al., 2008; Huang and Pope, 2009; Hu et al.,
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2014a). TLRs can be activated by a number of different factors
present within the RA joint (Goh and Midwood, 2012; Xu
et al., 2013; Lee et al., 2014). Limited data is available on the
regulation of TLRs via hypoxia and HIFs in the pathogenesis
of RA (Table 1). Kim et al. showed that hypoxia was able to
upregulate the expression of TLR-4 in macrophages via a HIF-
1α dependent pathway, leading to the activation of inflammatory
mediators in macrophages (e.g., cyclooxygenase-2, IL-6, and
RANTES; Kim et al., 2010). Furthermore, HIF-1α may also
help in the survival against TLR7/8-induced ATP depletion in
THP-1 human myeloid macrophages (Nicholas and Sumbayev,
2009). Overexpression of HIF-1α has been reported to enhance
RASF-mediated expansion of inflammatory Th1 and Th17
cells, as well as enhance inflammatory cytokine expression in
polyIC-stimulated RASF—thereby inducing a shift toward a pro-
inflammatory state in RA (Hu et al., 2014b, 2016). This suggests
that hypoxia and HIF-1α may function in conjunction with TLR-
stimulated innate immune responses to drive inflammation in
RA.
Immune cells also play an important role in synovial
inflammation. HIF-1α and HIF-2α are highly expressed in
immune cells, in particular macrophages, in the RA synovium
(Hollander et al., 2001; Brouwer et al., 2009; Hardy et al., 2014).
Resident macrophages (Type A synoviocytes) are primarily
located in the intimal lining of the RA synovium, and are
also found in the sub-lining layer and at the cartilage pannus
junction (Kinne et al., 2000; Szekanecz and Koch, 2007). In
response to hypoxia, macrophages upregulate HIFs to activate
pathways involved in proliferation, angiogenesis, and glucose
metabolism (Hollander et al., 2001; Brouwer et al., 2009; Hardy
et al., 2014). Cramer et al. reported a significant reduction in
synovitis, pannus formation, and disease progression with HIF-
1α knockout myeloid cells in the K/BxN serum transfer arthritis
model (Cramer et al., 2003). Deletion of HIF-1α in myeloid cells
reduced disease severity in both acute and chronic inflammation.
Similarly, macrophages lacking HIF-2α significantly suppressed
disease development in the K/BxN serum transfer arthritis
model, indicating an important role for HIF-2α in supporting
macrophages (Hardy et al., 2014).
HIF AND ANGIOGENESIS
Synovial angiogenesis is likely a consequence of synovial hypoxia
in RA (Konisti et al., 2012; Azizi et al., 2014). The increased
blood supply plays an important role in transporting immune
cells to the site of inflammation and supplying nutrients to the
pannus (Szekanecz and Koch, 2008). However, this dysregulated
vasculature within the RA joint is unable to provide adequate
oxygen supply (Taylor and Sivakumar, 2005; Kennedy et al.,
2010) and promotes the generation of reactive oxygen species
(ROS), which further enhances tissue damage within RA joints
(Taylor and Sivakumar, 2005). HIFs have been suggested to
regulate the expression of proangiogenic mediators, including
vascular endothelial growth factor (VEGF; Fava et al., 1994;
Koch et al., 1994), chemokine IL-8 (CXCL8; Ahn et al., 2008),
CC-chemokine ligand 20 (CCL20; also known as macrophage
inflammatory protein 3α, MIP-3α; Bosco et al., 2008), and
SDF-1 (del Rey et al., 2009; Santiago et al., 2011; Table 1).
VEGF is a key regulator of angiogenesis that is involved in
proliferation, migration, vascular tube formation, and prevention
of endothelial cell apoptosis (Elshabrawy et al., 2015). Both HIF-
1α and HIF-2α have been shown to increase the expression of
VEGF in the inflammatory joint region, as well as in cells derived
from RA synovium (Fava et al., 1994; Koch et al., 1994; Konisti
et al., 2012). It should be noted that other pathways dependent
or independent of HIF may also be involved in regulating the
expression of proangiogenic factors. For example, the Notch
signaling pathway has been shown to mediate hypoxia-induced
angiogenesis in inflammatory arthritis via the interaction of
Notch-1/HIF-1 through VEGF/Angiopoietin-2 (Gao et al., 2012)
In addition, pro-inflammatorymediators are also able to promote
RA angiogenesis, including cytokines [e.g., IL-17, IL-18, and
macrophage migration inhibitory factor (MIF)], chemokines
(CXCL12), growth factors (e.g., Ang1 and Ang2), proteases
(MMPs), and adhesion molecules (e.g., ICAM-1 and VCAM-1;
Elshabrawy et al., 2015).
HIF AND CARTILAGE DESTRUCTION
The articular cartilage is an avascular, aneural, and alymphatic
tissue, which is composed primarily of chondrocytes. The role of
HIFs in cartilage destruction in RA is not yet fully characterized,
with the majority of the work conducted in healthy articular
cartilage. Cells in the articular cartilage normally reside in a
hypoxic environment, with oxygen tension varying from 6–
10% at the joint surface to 1% in the deeper layers (Gibson
et al., 2008). HIF-1α acts as a survival factor in healthy cartilage
(Schipani et al., 2001; Pfander et al., 2003; Mariani et al., 2014),
and is essential in supporting chondrocyte energy generation
(Pfander et al., 2003, 2005; Mobasheri et al., 2005; Mariani et al.,
2014) and synthesis of the cartilage matrix (Pfander et al., 2005;
Mariani et al., 2014). Similarly, HIF-2α has been shown to have a
major role in anabolic responses in healthy human chondrocytes
(Lafont et al., 2007, 2008; Thoms et al., 2013; Zhang et al., 2015).
Initial results suggest that HIF may be involved in perpetuating
cartilage destruction in RA (Figure 1). As chronic inflammation
advances in RA, the hyperplastic pannus aggressively invades and
destroys the articular cartilage, particularly in the regions that
are contiguous with the proliferating synovial pannus (Williams
et al., 2000; Goldring, 2003; Otero and Goldring, 2007). The
synovial pannus contains invasive RASF cells which are the
main cells responsible for marginal cartilage destruction, via
the production of cartilage degrading enzymes called matrix
metalloproteinases (MMPs) (Abeles and Pillinger, 2006). Recent
studies have shown that membrane-type MMPs (MT1-MMP
and MT3-MMP) (Pap et al., 2000a,b) and cathepsin group of
proteases (cathepsin B, cathepsin L, capthesin D and capthesin K)
also contribute to cartilage destruction in RA (Pap et al., 2000b).
Hypoxia has been demonstrated to upregulate the levels of
MMPs in cells derived from RA synovium, although additional
pathways independent of HIF may also be involved (Canning
et al., 2001; Ben-Yosef et al., 2002; Cha et al., 2003; Akhavani
Frontiers in Pharmacology | www.frontiersin.org 4 June 2016 | Volume 7 | Article 184
Hua and Dias HIF in Rheumatoid Arthritis
et al., 2009;Table 1). Lee et al. demonstrated an increase inMMP-
1 protein expression and a corresponding decrease in MMP-
13 protein expression in IL-1β-stimulated FLS derived from
RA synovium under hypoxic conditions (Lee et al., 2012). This
differential effect of hypoxia on MMP production was shown
to be HIF-1α-dependent. MMP-3 has also been shown to be
directly controlled by the activation of HIF-1α in FLS (Ahn
et al., 2008). Interestingly, hypoxia-induced MMP-1 expression
was not significantly attenuated by knock-down ofHIF-1α, which
suggests other pathways are also involved in the expression of
MMPs (Ahn et al., 2008). Similarly, IL-17A was shown to induce
MMP-2 andMMP-9 expression, via a HIF-1α/NF-kB pathway (Li
et al., 2013c). Although the majority of the initial studies have
been conducted in vitro on cells derived from RA synovium,
further ex vivo and in vivo studies are warranted to assist in
strengthening our understanding of the complex role of HIF in
cartilage degradation in RA.
TARGETING HIF-REGULATED PATHWAYS
IN RA
Studies to date suggest that HIFs are promising targets for
novel RA treatments. Approaches that may be considered for
targeting hypoxia in RA cells include the use of hypoxia-activated
prodrugs, specific HIF inhibitors, gene therapy, or targeting
indirect pathways important in hypoxic cells. The majority of
these targeted therapies have come from research on the effects
of hypoxia on the growth of tumors (Phillips, 2016; Wigerup
et al., 2016). Hypoxic prodrugs were designed to be selectively
activated in hypoxic tissue, via reduction of the prodrug by
cellular reductases, thereby delivering the active agent to hypoxic
cells (Phillips, 2016). These therapeutic agents appear to use
hypoxia as a targeting mechanism to deliver therapeutic agents to
specific disease sites. Themain issue is the risk of off-target effects
due to the fact that hypoxia is a dynamic process that occurs
physiologically as well as in a multitude of diseases.
A number of HIF inhibitors have been developed that possess
inhibitory activity against cancer and HIF-related diseases (Ban
et al., 2016). There are considerably fewer selective and specific
HIF inhibitors compared to non-selective HIF inhibitors that
can target multiple pathways. Initial clinical trials of these
agents in various forms of cancer and other hypoxia-related
diseases have shown encouraging results (Konisti et al., 2012;
Wigerup et al., 2016). The majority of these compounds are
still in the early stages of development and have yet to be
assessed in clinical trials for RA (Manabe et al., 2008; del
Rey et al., 2009; Shankar et al., 2009; Wigerup et al., 2016).
Reasons for this include the complexity of the HIF pathway
in RA and their different mechanisms of action for HIF
inhibition, as well as pharmacokinetic and stability issues that
prevent these therapeutic agents from reaching the target cells
following administration (Ban et al., 2016; Wigerup et al.,
2016). Local administration of these compounds (e.g., intra-
articular injection) was proposed as an option to avoid any
pharmacokinetic issues or premature systemic degradation.
However, this route of administration is not always preferable in
conditions involving multiple sites and/or difficult to reach sites.
The use of delivery carriers may improve the efficacy of HIF-
related therapeutic agents following systemic administration,
by overcoming the pharmacokinetic and stability issues. The
best example of this is in the delivery of gene therapy
targeting HIFs, which have previously been shown to modulate
cellular responses in hypoxia-related diseases (Post et al., 2007;
Tal et al., 2008; Wang et al., 2008; del Rey et al., 2009;
Chen et al., 2016). The delivery of small interfering RNA
(siRNA) remains a challenge because of the lack of suitable
vectors. Transfection of fibroblasts with lentiviruses expressing
HIF-1α siRNA demonstrated significant reduction in HIF-1α
accumulation and VEGF mRNA levels in an in vivomodel of RA
(del Rey et al., 2009). Although viral vectors have shown to be
effective, the concerns surrounding their safety have limited their
application. Therefore, non-viral vectors have been investigated
as an alternative delivery platform for HIF gene delivery—
including liposomes (Wang et al., 2008; Chen et al., 2016) and
polymer-based nanoparticles (Liu et al., 2009). For example,
Wang et al. demonstrated that PEGylated liposomes loaded with
doxorubicin and antisense oligonucleotides targeted to HIF-1α
mRNA was able to effectively deliver the active agents into tumor
cells on nude mice bearing xenografts of multidrug-resistant
human ovarian carcinoma (Wang et al., 2008). The proposed
combination therapy increased the therapeutic efficacy of the
chemotherapy to an extent that was not able to be achieved by
administration of the individual components separately (Wang
et al., 2008). These results demonstrate that packaging active
agents targeting HIF-regulated pathways into delivery vehicles,
which are designed to accumulate specifically at sites of RA
disease, may improve therapeutic efficacy and reduce off-target
effects (Sercombe et al., 2015).
Indirect strategies to target downstream HIF signaling
pathways have also been investigated in RA. For example, many
therapeutic approaches have successfully resolved angiogenesis
in preclinical animal models of RA by administering antibodies
targeting VEGF or small molecule inhibitors targeting the VEGF
receptor (Maruotti et al., 2014). De Bandt et al. demonstrated
that systemic administration of an anti-VEGF-RI monoclonal
antibody (mAb) in the K/BxN mouse model of RA was able
to delay the onset of arthritis, attenuate its intensity, and
prevent joint destruction (De Bandt et al., 2003). Interestingly,
Lu et al. reported that administration of anti-VEGF antibody
before the onset of experimental arthritis was able to delay the
onset and reduce the severity of disease in the CIA model,
whereas administration post-onset of disease had no effect on the
progression or severity of the arthritis (Lu et al., 2000). The study
suggested that VEGF may have a crucial role predominantly
in the early stage of arthritis development. Unfortunately, a
number of these promising therapies have not yet been tested
in clinical trials for RA. Those which have been tested in
clinical trials were unable to translate the promising results in
preclinical studies into successful treatment strategies for RA
patients. This includes the discontinuation of phase II clinical
trials studying MMP inhibitors in RA (Thabet and Huizinga,
2006; Dorman et al., 2010), as well as reduced efficacy of repeated
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administration of anti-ICAM-1mAb in RA patients (Kavanaugh
et al., 1996, 1997). This suggest that human RA is highly complex
and heterogeneous, which involves multiple pathways occurring
simultaneously to perpetuate disease (Elshabrawy et al., 2015).
CONCLUSION
Accumulating evidence supports hypoxia and HIFs in regulating
a number of important pathophysiological characteristics of
RA, including synovial inflammation, angiogenesis, and cartilage
destruction. Therefore, HIF inhibitors are likely to target multiple
important RA processes. Experimental and clinical data have
confirmed the upregulation of both HIF-1α and HIF-2α in RA.
At this time, the relative importance of each isoform in RA
pathology and disease severity is still unclear. These two isoforms
show different sensitivity to oxygen tension and display distinct,
and sometimes opposing, cellular activities. In addition, further
studies are required to clarify the interrelationship between HIFs
and other simultaneous pathways in perpetuating RA disease.
This will allow us to determine whether specific HIF-1α or
HIF-2α inhibition is likely to be required for successful clinical
outcomes in RA. To optimize their effects, HIF inhibitors may
require encapsulation within delivery vehicles directed toward
affected RA tissue to improve therapeutic accumulation and
stability following systemic administration, as well as reduce
off-target effects.
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